Breaking the Amendment Cycle: How Agentic AI Enables Smarter Clinical Trial Design and Operations
Faster trials are not a vanity metric. They reflect an undeniable need: getting safe therapies to patients sooner.
You Can Now Bet on Clinical Trials Like Playoff Games, But Health Execs Say It Crosses a Line
Prediction market Kalshi launched betting markets tied to clinical trial results and FDA approvals. Healthcare leaders warn the model could invite insider trading and distort the integrity of the research outcomes it's meant to forecast.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Why Real-World Evidence Is Becoming the Missing Link Between Innovation and Patient Care in Oncology
Organizations that can generate and apply high-quality, clinically grounded evidence will be better positioned to close the gap between what is proven in trials and what is achieved in practice.
Transforming CTMS: An Operating Layer for Real-Time Trial Execution
CTMS platforms do not lack capability. They reflect an earlier architectural priority.
Verily & Samsung Team Up to Bring Smartwatch Data into Clinical Trials
Verily and Samsung are partnering to integrate data from Galaxy smartwatches into Verily’s Pre platform. The goal is to create an end-to-end system that pharma researchers can use to deploy wearable devices in studies, analyze patient data remotely and then interpret the results.
Roche, Zealand Pharma Obesity Drug Meets Clinical Trial’s Weight Loss Goals, But Can It Compete?
Petrelintide posted Phase 2 results showing tolerability comparable to a placebo, but average weight loss that was less than what analysts expected. The Zealand Pharma drug, in development under a partnership with Roche, is a peptide engineered to activate the amylin receptor.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Valo Health CEO: We Don’t Want Investors To Drive the Science
Brian Alexander feels the current system of drug development is shaped by biotech investor expectations. Valo Health is eschewing that path.
The 4 Biotech Companies on Track to IPO this Week Despite the Government Shutdown
Across all industries, the total number of companies on track to go public could make this week the most active for IPOs since 2021. Despite the partial government shutdown, there are paths biotechs can pursue to the public markets.
How DiME’s New Pediatric Rare Disease Project Could Make Clinical Trials Faster
The Digital Medicine Society (DiME) launched a new set of FDA-aligned digital measures to standardize how outcomes are tracked in pediatric rare disease trials. The framework aims to make trials faster and more efficient, giving researchers and drugmakers a practical roadmap for developing new therapies for children who often have no effective treatment options.
Roche Obesity Drug’s Phase 2 Results Are Competitive, But True Test May Come From Combo Studies
Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity.
presented by
Automation Didn’t Dehumanize Care. Bad Systems Did.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.
Crescent Bio Expands Its Cancer Drug Combo Ambitions With New Kelun-Biotech Alliance
Crescent Biopharma gains rights to a Kelun-Biotech antibody drug conjugate it plans to test in combination with its lead cancer drug, a bispecific antibody designed to block PD-1 and VEGF. Separately, Crescent raised $185 million in a private placement to support its clinical trial plans.
Cleveland Clinic Taps Dyania Health to Speed Up Clinical Trials with AI
Cleveland Clinic is expanding its use of Dyania Health’s AI platform across the health system to speed up clinical trial recruitment. The system quickly scans patient records to identify eligible participants, aiming to give more patients access to trials and speed up development timelines for new therapies.
Carving a Path Toward Pragmatic Innovation in Clinical Trials
Prioritizing risk-based management, data science, smart automation, standards, and patient optionality are critical for the industry to keep up with market changes. The recent FDA guidance that encourages ‘pragmatic trials’ in specific scenarios is a move in the right direction.
AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma
AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile.
Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia
The ability to harness real-world insights at scale empowers life sciences companies and clinicians to develop more targeted therapies, improve patient outcomes, and drive evidence-based innovation in BPH treatment.